Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Jul 30, 2015 12:11pm

106 Views

Post# 23976158

RE:RE:RE:RE:We need some confidence and action!

Correction: Hypothetically, if they are able to enroll 1200 patients by the start of EACH of the 3 quarters Q1 2016, Q2 2016 and Q3 2016, (reaching 3600 patients by start of Q3 2016), then by the end of Q3 2016 they should hit the 250 MACE mark.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale